In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Follow-on offering nets $81.6mm for Orexigen

Executive Summary

Obesity-focused Orexigen Therapeutics netted $81.6mm through a follow-on public offering of 10mm common shares (including the overallotment) at $7.50. The company plans to use part of the proceeds to prepare the NDA for its lead Contrave, and for ongoing Phase II trials of Empatic. Both candidates are under development for weight loss.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register